TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice

Melanie D. King, Cargill Herley Alleyne, Krishnan Michael Dhandapani

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

•R-7050, a novel TNFR antagonist, reduces neurovascular injury after ICH.•Pharmacological inhibition of TNFR improves outcomes after ICH.•TNFR may represent a viable therapeutic target after ICH. Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, exhibits the highest acute mortality and the worst long-term prognosis of all stroke subtypes. Unfortunately, treatment options for ICH are lacking due in part to a lack of feasible therapeutic targets. Inflammatory activation is associated with neurological deficits in pre-clinical ICH models and with patient deterioration after clinical ICH. In the present study, we tested the hypothesis that R-7050, a novel cell permeable triazoloquinoxaline inhibitor of the tumor necrosis factor receptor (TNFR) complex, attenuates neurovascular injury after ICH in mice. Up to 2. h post-injury administration of R-7050 significantly reduced blood-brain barrier opening and attenuated edema development at 24. h post-ICH. Neurological outcomes were also improved over the first 3 days after injury. In contrast, R-7050 did not reduce hematoma volume, suggesting the beneficial effects of TNFR inhibition were downstream of clot formation/resolution. These data suggest a potential clinical utility for TNFR antagonists as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalNeuroscience Letters
Volume542
DOIs
StatePublished - May 10 2013

Fingerprint

Tumor Necrosis Factor Receptors
Cerebral Hemorrhage
Tumor Necrosis Factor-alpha
Wounds and Injuries
Stroke
Therapeutics
Blood-Brain Barrier
Hematoma
Edema
Pharmacology
Mortality

Keywords

  • BBB
  • Blood-brain barrier
  • Edema
  • Hemorrhage
  • ICH
  • Inflammation
  • RIP1
  • Stroke
  • TNF-α
  • TNFR
  • TRADD
  • TRAF

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. / King, Melanie D.; Alleyne, Cargill Herley; Dhandapani, Krishnan Michael.

In: Neuroscience Letters, Vol. 542, 10.05.2013, p. 92-96.

Research output: Contribution to journalArticle

@article{5721280932144002bfa8b6cec6b74888,
title = "TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice",
abstract = "•R-7050, a novel TNFR antagonist, reduces neurovascular injury after ICH.•Pharmacological inhibition of TNFR improves outcomes after ICH.•TNFR may represent a viable therapeutic target after ICH. Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, exhibits the highest acute mortality and the worst long-term prognosis of all stroke subtypes. Unfortunately, treatment options for ICH are lacking due in part to a lack of feasible therapeutic targets. Inflammatory activation is associated with neurological deficits in pre-clinical ICH models and with patient deterioration after clinical ICH. In the present study, we tested the hypothesis that R-7050, a novel cell permeable triazoloquinoxaline inhibitor of the tumor necrosis factor receptor (TNFR) complex, attenuates neurovascular injury after ICH in mice. Up to 2. h post-injury administration of R-7050 significantly reduced blood-brain barrier opening and attenuated edema development at 24. h post-ICH. Neurological outcomes were also improved over the first 3 days after injury. In contrast, R-7050 did not reduce hematoma volume, suggesting the beneficial effects of TNFR inhibition were downstream of clot formation/resolution. These data suggest a potential clinical utility for TNFR antagonists as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH.",
keywords = "BBB, Blood-brain barrier, Edema, Hemorrhage, ICH, Inflammation, RIP1, Stroke, TNF-α, TNFR, TRADD, TRAF",
author = "King, {Melanie D.} and Alleyne, {Cargill Herley} and Dhandapani, {Krishnan Michael}",
year = "2013",
month = "5",
day = "10",
doi = "10.1016/j.neulet.2013.02.051",
language = "English (US)",
volume = "542",
pages = "92--96",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice

AU - King, Melanie D.

AU - Alleyne, Cargill Herley

AU - Dhandapani, Krishnan Michael

PY - 2013/5/10

Y1 - 2013/5/10

N2 - •R-7050, a novel TNFR antagonist, reduces neurovascular injury after ICH.•Pharmacological inhibition of TNFR improves outcomes after ICH.•TNFR may represent a viable therapeutic target after ICH. Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, exhibits the highest acute mortality and the worst long-term prognosis of all stroke subtypes. Unfortunately, treatment options for ICH are lacking due in part to a lack of feasible therapeutic targets. Inflammatory activation is associated with neurological deficits in pre-clinical ICH models and with patient deterioration after clinical ICH. In the present study, we tested the hypothesis that R-7050, a novel cell permeable triazoloquinoxaline inhibitor of the tumor necrosis factor receptor (TNFR) complex, attenuates neurovascular injury after ICH in mice. Up to 2. h post-injury administration of R-7050 significantly reduced blood-brain barrier opening and attenuated edema development at 24. h post-ICH. Neurological outcomes were also improved over the first 3 days after injury. In contrast, R-7050 did not reduce hematoma volume, suggesting the beneficial effects of TNFR inhibition were downstream of clot formation/resolution. These data suggest a potential clinical utility for TNFR antagonists as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH.

AB - •R-7050, a novel TNFR antagonist, reduces neurovascular injury after ICH.•Pharmacological inhibition of TNFR improves outcomes after ICH.•TNFR may represent a viable therapeutic target after ICH. Intracerebral hemorrhage (ICH), the most common form of hemorrhagic stroke, exhibits the highest acute mortality and the worst long-term prognosis of all stroke subtypes. Unfortunately, treatment options for ICH are lacking due in part to a lack of feasible therapeutic targets. Inflammatory activation is associated with neurological deficits in pre-clinical ICH models and with patient deterioration after clinical ICH. In the present study, we tested the hypothesis that R-7050, a novel cell permeable triazoloquinoxaline inhibitor of the tumor necrosis factor receptor (TNFR) complex, attenuates neurovascular injury after ICH in mice. Up to 2. h post-injury administration of R-7050 significantly reduced blood-brain barrier opening and attenuated edema development at 24. h post-ICH. Neurological outcomes were also improved over the first 3 days after injury. In contrast, R-7050 did not reduce hematoma volume, suggesting the beneficial effects of TNFR inhibition were downstream of clot formation/resolution. These data suggest a potential clinical utility for TNFR antagonists as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH.

KW - BBB

KW - Blood-brain barrier

KW - Edema

KW - Hemorrhage

KW - ICH

KW - Inflammation

KW - RIP1

KW - Stroke

KW - TNF-α

KW - TNFR

KW - TRADD

KW - TRAF

UR - http://www.scopus.com/inward/record.url?scp=84876728540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876728540&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2013.02.051

DO - 10.1016/j.neulet.2013.02.051

M3 - Article

C2 - 23499961

AN - SCOPUS:84876728540

VL - 542

SP - 92

EP - 96

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -